Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07755436 |
| Title | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | ArriVent BioPharma, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |